Kyu-Tae Kim, PhD

I received PhD degree from the University of New South Wales. I was a Postdoctoral Fellow at Johns Hopkins University School of Medicine. Then I joined the Faculty of Health, School of Biomedical Sciences and Pharmacy at the University of Newcastle. I started biotech career as Chief Scientific Officer and Director of BD&L at AbClon Inc., an innovative therapeutic antibody drug company. Currently I serve Pharos iBio as Chief Business Officer and co-CEO of Pharos Therapeutics which is full subsidiary of the Pharos iBio. I have many experiences to present research and business development outcomes in the multiple audiences including BIO USA and Bio Europe. If you allow me to present our company, I would like to present about our AI-based drug development platform and PHI-101, a novel FLT3/CHK2 inhibitor, which is currently in clinical phase 1 for AML and Ovarian Cancer patients. I hope the committee would kindly offer me to present who we are and what we are developing at the BIO.